Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit on behalf of shareholders of uniQure N.V. (NASDAQ: QURE) due to allegations of misleading investors regarding the company's business operations and the approval status of its pivotal study for a drug candidate targeting Huntington's Disease [1] Group 1: Allegations Against uniQure N.V. - The lawsuit claims that uniQure misrepresented the approval status of its pivotal study by the U.S. Food and Drug Administration (FDA) [1] - It is alleged that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] - The lawsuit asserts that the statements made by uniQure regarding its business, operations, and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [1] Group 2: Class Action Participation - Shareholders who wish to serve as lead plaintiffs must file their motions by April 13, 2026 [1] - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members if they choose [1] - All legal representation is provided on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [1]